arrow
T

Tjalling Bosse

Leiden University
H指数:71
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

早期子宫内膜样卵巢癌患者淋巴结转移、手术及辅助治疗(LEOPARD)——一项跨国团队倡议

2026-05-050
OAAI
The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations

子宫内膜癌中的沙漠免疫表型:一个具有不良预后和可靶向突变的独特亚群

2026-04-100
OAAI
Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER Status

按ER状态分层的无特定分子表型(NSMP)高级别子宫内膜癌的临床病理及分子特征

2026-01-014
PRE
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

高危子宫内膜癌患者中辅助放化疗与单纯放疗的比较(PORTEC-3):一项随机III期试验的10年临床结局及基于分子分型的事后分析

2025-09-050
OAAI
Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer

一种用于预测高级别浆液性卵巢癌患者对铂类为基础疗法临床反应的离体3D微肿瘤检测平台

2025-08-300
OAAI
Capturing breast cancers’ copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond

在常规病理学中捕获乳腺癌的拷贝数景观:利用低分辨率、全基因组测序来识别同源重组缺陷(HRD)及其相关特征

2025-08-230
PRE
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025

ESGO–ESTRO–ESP关于子宫内膜癌患者管理的指南:2025年更新

2025-07-280
PRE
APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma—a multicenter, single-arm, phase II, clinical proof-of-concept study

APOLLO:原发性外阴鳞状细胞癌的新辅助帕博利珠单抗治疗——一项多中心、单臂、II期概念验证临床研究

2025-04-170
OAAI
Retinoblastoma Protein Loss in p53 Abnormal Endometrial Carcinoma: Histologic and Clinicopathological Correlates

p53异常子宫内膜癌中的视网膜母细胞瘤蛋白丢失: 组织学和临床病理相关性

2025-03-010
OAAI